Author: admin

Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Parkinson’s Disease pipeline constitutes 130+ key companies continuously working towards developing 150+ Parkinson’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Parkinson’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.

 

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Parkinson’s Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years.

  • Parkinson’s Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment

  • Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.

  • In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

  • In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

  • In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

  • In December 2024, Belgian pharmaceutical company UCB decided to discontinue the development of minzasolmin for Parkinson’s disease after the ORCHESTRA study did not achieve its primary or secondary endpoints. In the ORCHESTRA proof-of-concept trial (NCT04658186), minzasolmin—an investigational oral small-molecule inhibitor targeting alpha-synuclein misfolding—failed to show superiority over placebo.

  • In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson’s Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research’s network, will be a site for PhotoPharmics’ LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson’s symptoms.

  • In September 2024, AbbVie’s recently acquired Parkinson’s disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

 

Parkinson’s Disease Overview

Parkinson’s disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson’s disease experience difficulties with movement control.

 

Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

 

Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:

  • KM-819: FAScinate Therapeutics

  • Prasinezumab: Hoffmann-La Roche

  • P2B001: Pharma Two B Ltd.

  • NPT1220-478: Neuropore Therapies, Inc.

  • Dapansutrile: Olatec Therapeutics

  • UCB7853: UCB Biopharma

  • UB-312: Vaxxinity

  • Emrusolmin: Modag

  • PT320: Peptron

  • KDT-3594: Kissei Pharmaceutical

  • Tavapadon: Cerevel Therapeutics

 

Parkinson’s Disease Route of Administration

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • NA

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

 

Parkinson’s Disease Molecule Type

Parkinson’s Disease Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

 

Parkinson’s Disease Pipeline Therapeutics Assessment

  • Parkinson’s Disease Assessment by Product Type

  • Parkinson’s Disease By Stage and Product Type

  • Parkinson’s Disease Assessment by Route of Administration

  • Parkinson’s Disease By Stage and Route of Administration

  • Parkinson’s Disease Assessment by Molecule Type

  • Parkinson’s Disease by Stage and Molecule Type

 

DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies

 

Some of the key companies in the Parkinson’s Disease Therapeutics Market include:

Key companies developing therapies for Parkinson’s Disease are – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.

 

Parkinson’s Disease Pipeline Analysis:

The Parkinson’s Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.

  • Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies

 

Parkinson’s Disease Pipeline Market Drivers

  • Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.

 

Parkinson’s Disease Pipeline Market Barriers

  • However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.

 

Scope of Parkinson’s Disease Pipeline Drug Insight

  • Coverage: Global

  • Key Parkinson’s Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

  • Key Parkinson’s Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

  • Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

  • Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

 

Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Parkinson’s Disease Report Introduction

2. Parkinson’s Disease Executive Summary

3. Parkinson’s Disease Overview

4. Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Parkinson’s Disease Pipeline Therapeutics

6. Parkinson’s Disease Late Stage Products (Phase II/III)

7. Parkinson’s Disease Mid Stage Products (Phase II)

8. Parkinson’s Disease Early Stage Products (Phase I)

9. Parkinson’s Disease Preclinical Stage Products

10. Parkinson’s Disease Therapeutics Assessment

11. Parkinson’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Parkinson’s Disease Key Companies

14. Parkinson’s Disease Key Products

15. Parkinson’s Disease Unmet Needs

16 . Parkinson’s Disease Market Drivers and Barriers

17. Parkinson’s Disease Future Perspectives and Conclusion

18. Parkinson’s Disease Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea

Census Dots: A New Interactive Dot Map Reveals the Demographic Makeup of America

Census Dots is an interactive map displaying all 331 million Americans from the decennial census, color-coded by race. Users can explore demographic patterns from national to neighborhood levels. The project revives a similar 2010 map, with future plans to add additional historical and socioeconomic data.

BROOKLYN, NY – Census Dots is an updated demographic dot map of the United States, displaying all 331 million Americans recorded in the 2020 Census, color-coded by race. The map is interactive and zoomable, allowing exploration at the national, state, city, and neighborhood levels. Dedicated pages exist for both states and municipalities — for example, Texas or Los Angeles, CA — providing statistics on individual geographies and allowing easy comparison between neighbors. Census Dots intends to make it easier for journalists, researchers, and the public to visualize census data and explore demographic trends across the United States.

The Census Dots map was created following the loss of Dustin Cable’s popular 2010 Racial Dot Map, which he created at UVA’s Weldon Cooper Center for Public Service. Citing outdated data and a lack of resources, the Cooper Center ceased hosting the map in 2022 and it disappeared from the web. “When the Cooper Center took down the 2010 Racial Dot Map, it left a huge void,” said Luke Loreti, creator of Census Dots. “I wanted to bring that resource back — updated for the 2020 Census—so people could again explore the data in an intuitive, visually compelling format.”

Similar to previous dot maps, the map was created by combining two census data sources: population counts published in the State Redistricting Data and Shapefiles defining the census geographies. The decennial census provides population counts down to the census block level — an area roughly the size of a city block — enabling a high degree of geographic accuracy. The dots within a given census block are placed at random, which is why some dots may appear in unlikely places like parking lots or bodies of water. The data comes together to create an extremely visually striking map, both when viewed at the national scale and when zoomed into individual neighborhoods. It often illustrates the stark divides that persist across much of the country.

The Census Dots map launches with data from the most recent decennial census, with plans to incorporate additional datasets and views in the coming months. Future updates will include historical comparisons between census years and additional socioeconomic data layers.

The map is optimized for both desktop and mobile use. The project was enabled by the previous work of Dustin Cable, Peter Richardson, Erica Fischer, Brandon Martin-Anderson, and others who have mapped census data.

To explore your city, visit www.censusdots.com.

Census Dots is a project created by Luke Loreti, a software engineer working in the edtech space. His love of mapping technologies and urbanism drove him to create a new census dot map. Previously, he co-founded a healthtech company, did VR research at the MIT Media Lab, and received a certificate in Urban Planning & Design from Harvard GSD.

Media Contact
Company Name: Census Dots
Contact Person: Luke Loreti
Email: Send Email
City: Brooklyn
State: NY
Country: United States
Website: https://www.censusdots.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Census Dots: A New Interactive Dot Map Reveals the Demographic Makeup of America

Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune

The Key Parainfluenza Virus Infection Companies in the market include – Ansun Biopharma, AlloVir, MedImmune LLC, and others.

DelveInsight’s “Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Parainfluenza Virus Infection, offering comprehensive insights into the Parainfluenza Virus Infection revenue trends, prevalence, and treatment landscape. The report delves into key Parainfluenza Virus Infection statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Parainfluenza Virus Infection therapies. Additionally, we cover the landscape of Parainfluenza Virus Infection clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Parainfluenza Virus Infection treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Parainfluenza Virus Infection space.

 

To Know in detail about the Parainfluenza Virus Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parainfluenza Virus Infection Market Forecast

 

Some of the key facts of the Parainfluenza Virus Infection Market Report:

  • The Parainfluenza Virus Infection market size was valued ~USD 259 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In December 2024, Blue Lake Biotechnology, Inc., a clinical-stage company specializing in intranasal vaccines, announced positive preliminary results from its Phase 1/2a clinical study of BLB201, an intranasal RSV vaccine candidate. The analysis included the first 63 infants and young children enrolled in the trial. The company develops parainfluenza virus 5 (PIV5)-vectored vaccines designed to engage the full immune system for protection against severe infectious diseases.

  • In November 2024, Blue Lake Biotechnology, Inc., a clinical-stage company specializing in intranasal vaccines using parainfluenza virus 5 (PIV5)-vectored technology to activate the full immune system for protection against serious infections, along with its affiliate CyanVac LLC, today announced results from a 227-participant Phase 2a clinical trial. The data demonstrate the safety, tolerability, immunogenicity, and efficacy of CVXGA, the company’s intranasal vaccine candidate for COVID-19.

  • In 2023, the US held the largest market share in the 7MM, accounting for 68%, followed by EU4 and the UK, with growth expected throughout the forecast period (2024–2034).

  • In 2023, EU4 and the UK accounted for approximately 23% of the total market share in the 7MM.

  • Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, MedImmune LLC, and others

  • Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, MEDI-534, and others

  • The Parainfluenza Virus Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parainfluenza Virus Infection pipeline products will significantly revolutionize the Parainfluenza Virus Infection market dynamics.

  • DelveInsight estimates that there were 2,709,923 cases of parainfluenza virus infection in the 7MM in 2023.

  • In 2023, the United States recorded 1,456,399 new cases of parainfluenza virus, with numbers expected to rise during the forecast period.

  • According to estimates, the total number of incident cases of parainfluenza virus infection in EU4 and the UK was 991,115 in 2023. Among the EU4 countries, Spain reported the highest proportion of cases, while the UK had the fewest.

  • Estimates indicate that Japan reported approximately 262,409 cases of parainfluenza virus infection in 2023, with numbers expected to rise by 2034.

 

Parainfluenza Virus Infection Overview

Parainfluenza virus infection is a respiratory illness caused by the parainfluenza viruses, which are part of the paramyxovirus family. These viruses primarily affect the upper and lower respiratory tract, leading to symptoms similar to the common cold, such as fever, cough, runny nose, and sore throat. In more severe cases, particularly in young children and individuals with weakened immune systems, parainfluenza virus infection can lead to conditions like croup, bronchitis, or pneumonia. The infection is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes. There is no specific antiviral treatment, but supportive care is typically provided to manage symptoms.

 

Get a Free sample for the Parainfluenza Virus Infection Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market

 

Parainfluenza Virus Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Parainfluenza Virus Infection Epidemiology Segmentation:

The Parainfluenza Virus Infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Parainfluenza Virus Infection

  • Prevalent Cases of Parainfluenza Virus Infection by severity

  • Gender-specific Prevalence of Parainfluenza Virus Infection

  • Diagnosed Cases of Episodic and Chronic Parainfluenza Virus Infection

 

Download the report to understand which factors are driving Parainfluenza Virus Infection epidemiology trends @ Parainfluenza Virus Infection Epidemiology Forecast

 

Parainfluenza Virus Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parainfluenza Virus Infection market or expected to get launched during the study period. The analysis covers Parainfluenza Virus Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parainfluenza Virus Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Parainfluenza Virus Infection Therapies and Key Companies

  • DAS181: Ansun Biopharma

  • ALVR106: AlloVir

  • Oplunofusp: Ansun Biopharma

  • MEDI-534: MedImmune LLC

 

Discover more about therapies set to grab major Parainfluenza Virus Infection market share @ Parainfluenza Virus Infection Treatment Landscape

 

Parainfluenza Virus Infection Market Drivers

  • Rising Incidence

  • Advancements in Diagnostic Tools

  • Growing Awareness

  • Development of Vaccines

  • Supportive Healthcare Policies

 

Parainfluenza Virus Infection Market Barriers

  • Lack of Specific Treatments

  • High R&D Costs

  • Limited Awareness in Low-Income Regions

  • Seasonal Variability

  • Regulatory Challenges

 

Scope of the Parainfluenza Virus Infection Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, MedImmune LLC, and others

  • Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, MEDI-534, and others

  • Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection current marketed and Parainfluenza Virus Infection emerging therapies

  • Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and Parainfluenza Virus Infection market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Parainfluenza Virus Infection Unmet Needs, KOL’s views, Analyst’s views, Parainfluenza Virus Infection Market Access and Reimbursement

 

To know more about Parainfluenza Virus Infection companies working in the treatment market, visit @ Parainfluenza Virus Infection Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Parainfluenza Virus Infection Market Report Introduction

2. Executive Summary for Parainfluenza Virus Infection

3. SWOT analysis of Parainfluenza Virus Infection

4. Parainfluenza Virus Infection Patient Share (%) Overview at a Glance

5. Parainfluenza Virus Infection Market Overview at a Glance

6. Parainfluenza Virus Infection Disease Background and Overview

7. Parainfluenza Virus Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Parainfluenza Virus Infection

9. Parainfluenza Virus Infection Current Treatment and Medical Practices

10. Parainfluenza Virus Infection Unmet Needs

11. Parainfluenza Virus Infection Emerging Therapies

12. Parainfluenza Virus Infection Market Outlook

13. Country-Wise Parainfluenza Virus Infection Market Analysis (2020–2034)

14. Parainfluenza Virus Infection Market Access and Reimbursement of Therapies

15. Parainfluenza Virus Infection Market Drivers

16. Parainfluenza Virus Infection Market Barriers

17. Parainfluenza Virus Infection Appendix

18. Parainfluenza Virus Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

The Key Fabry Disease Companies in the market include – Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others.

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast

 

Some of the key facts of the Fabry Disease Market Report:

  • The Fabry Disease market size was valued ~USD 1,306 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In December 2024, Exegenesis Bio, a global clinical-stage gene therapy company, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to EXG110, an innovative gene therapy for Fabry disease—a rare lysosomal disorder characterized by excessive lipid accumulation in tissues, leading to renal failure, cardiac complications, and strokes.

  • In 2022, the U.S. had the largest Fabry Disease market size among the 7MM, valued at approximately USD 625 million, with projections for further growth by 2032

  • Within the European Union, the United Kingdom and Italy represent the largest market shares, with figures reaching USD 158 million and USD 150 million respectively in 2022. Conversely, Spain holds the lowest market position during the same period, with a recorded figure of USD 44 million.

  • In 2022, the Fabry Disease market size reached its peak in the US among the seven major markets (7MM), amounting to approximately USD 625 million. This figure is projected to continue rising through to 2032.

  • In 2022, there were a total of 15,290 diagnosed prevalent cases of Fabry Disease in the seven major markets (7MM), with the highest number of cases recorded in the United States. The EU4 countries and the UK accounted for 5,245 cases, while Japan had 1,690 cases.

  • In the US, 4,345 males and 4,011 females were affected by Fabry disease in 2022. These numbers are expected to rise by 2032.

  • In 2022, the UK had the highest number of diagnosed prevalent cases of Fabry Disease among the EU4 and the UK, with approximately 58% of the cases being female and 42% male. These numbers are anticipated to change during the forecast period.

  • DelveInsight analysts reported that the diagnosed prevalent cases of Fabry Disease in 2022 were categorized into classic and late-onset phenotypes. There were 3,342 cases of the classic phenotype and 5,013 cases of the late-onset phenotype in the seven major markets (7MM).

  • Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

  • Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

  • The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States

  • The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

 

Fabry Disease Overview

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency or malfunction of the enzyme alpha-galactosidase A. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3) in the body’s cells. When alpha-galactosidase A is deficient or dysfunctional, Gb3 accumulates in various tissues and organs, leading to a wide range of symptoms.

 

Get a Free sample for the Fabry Disease Market Report:

https://www.delveinsight.com/report-store/fabry-disease-market

 

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Fabry Disease

  • Prevalent Cases of Fabry Disease by severity

  • Gender-specific Prevalence of Fabry Disease

  • Diagnosed Cases of Episodic and Chronic Fabry Disease

 

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast

 

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Fabry Disease Therapies and Key Companies

  • ELFABRIO (PRX-102): Chiesi and Protalix Biotherapeutics

  • Venglustat: Sanofi Genzyme

  • Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics

  • PRX-102: Protalix Biotherapeutics

  • AVR-RD-01: AVROBIO

  • Venglustat: Sanofi Genzyme

  • ST-920: Sangamo Therapeutics

  • FLT190: Freeline Therapeutics

  • 4D-310: 4D Molecular Therapeutics

  • Lucerastat: Idorsia Pharmaceuticals

  • Moss-aGal: Greenovation Biotech GMBH

  • PRX-102: ICON plc

  • pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.

  • migalastat: Amicus Therapeutics

  • Agalsidase alfa: Shire

 

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market

 

Fabry Disease Market Strengths

  • Emphasis on NBS to detect Fabry Disease at an early stage allows for timely treatment with better risk- benefit assessment.

  • The growing Fabry Disease pool is expected to propel the treatment market, adding opportunities for new pharma players.

 

Fabry Disease Market Opportunities

  • Development of potential biomarkers allows tracking the severity and predicting the progression of the disease, as well as checking the effectiveness of therapeutic intervention.

  • The shortcomings of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches.

 

Scope of the Fabry Disease Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

  • Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

  • Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies

  • Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

 

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2019–2032)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17. Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

Achondroplasia Market on Track for Major Expansion by 2034, According to DelveInsight | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic Inc

The Key Achondroplasia Companies in the marklet include – BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others.

 

DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast

 

Some of the key facts of the Achondroplasia Market Report:

  • The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic disorders, announced today that the FDA has granted Breakthrough Therapy Designation to oral infigratinib, which is being developed for pediatric achondroplasia. This designation aims to accelerate the development and regulatory review of drugs in the U.S. that meet strict criteria. To qualify, a drug must show initial clinical evidence of potentially significant improvement on clinically meaningful endpoints compared to existing treatments.

  • In the United States, achondroplasia impacts a slightly higher percentage of females (51.2%) compared to males (48.8%). This slight difference may be attributed to genetic or biological factors that contribute to its somewhat greater prevalence in females.

  • In 2023, the total number of diagnosed prevalent cases of achondroplasia in Japan and the US was approximately 18,000, with expectations for this number to increase in the coming years.

  • In 2023, Japan had around 3,000 diagnosed prevalent cases of achondroplasia.

  • The epidemiology model categorizes age-specific cases into nine groups: 0–4, 5–10, 11–15, 16–20, 21–30, 31–40, 41–50, 51–60, and over 60. DelveInsight’s estimates indicate that the 5–10 age group was the most affected in the US, with around 4,000 cases reported in 2023.

  • Achondroplasia is estimated to occur in 1 out of every 15,000 to 40,000 live births, making it one of the most prevalent types of skeletal dysplasia.

  • Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

  • Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

  • The Achondroplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

 

Achondroplasia Overview

Achondroplasia is a genetic disorder and the most common form of dwarfism, characterized by abnormal bone growth that results in short stature with disproportionately short arms and legs, a larger head, and distinctive facial features. It is caused by mutations in the *FGFR3* gene, which affects cartilage formation and bone growth. This condition is typically inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder. While people with achondroplasia often have normal intelligence and lifespan, they may experience certain health challenges such as spinal stenosis, ear infections, and respiratory issues.

 

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/fabry-disease-market

 

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Achondroplasia

  • Prevalent Cases of Achondroplasia by severity

  • Gender-specific Prevalence of Achondroplasia

  • Diagnosed Cases of Episodic and Chronic Achondroplasia

 

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast

 

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Achondroplasia Therapies and Key Companies

  • VOXZOGO (vosoritide): BioMarin Pharmaceuticals

  • Infigratinib: BridgeBio/ QED Therapeutics

  • RBM-007: Ribomic Inc

  • Sanofi: SAR-442501

  • Recombinant human growth hormone: Changchun GeneScience Pharma

  • Infigratinib: QED Therapeutics, Inc.

  • TransCon CNP: Ascendis Pharma A/S

  • Infigratinib: QED Therapeutics, Inc

  • vosoritide: BioMarin Pharmaceuticals

  • BMN 111: BioMarin Pharmaceutical

 

Discover more about therapies set to grab major Achondroplasia market share @ Achondroplasia Treatment Landscape

 

Scope of the Achondroplasia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

  • Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

  • Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies

  • Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Achondroplasia Unmet Needs, KOL’s views, Analyst’s views, Achondroplasia Market Access and Reimbursement

 

To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2020–2034)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17. Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Achondroplasia Market on Track for Major Expansion by 2034, According to DelveInsight | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic Inc

Rad Web Hosting Focuses Efforts on CO₂ Removal, Enhanced Sustainability Initiatives

“Rad Web Hosting Focuses Efforts on CO? Removal, Enhanced Sustainability Initiatives”
Rad Web Hosting Announces a more robust sustainability initiative

Rad Web Hosting, a leading provider of web hosting and cloud services, has announced a renewed commitment to sustainability by prioritizing carbon dioxide (CO₂) removal initiatives and expanding its eco-friendly practices. This move underscores the company’s dedication to minimizing its environmental footprint while delivering high-performance hosting solutions.

Recognizing the impact of data centers on global carbon emissions, Rad Web Hosting is taking proactive steps to offset its energy consumption and contribute to a greener future. Key initiatives include:

  • CO₂ Removal Investments – Partnering with leading carbon removal organizations to invest in innovative solutions that capture and store CO₂, helping to reduce the industry’s overall impact.
  • Renewable Energy Usage – Expanding reliance on renewable energy sources for data center operations, reducing dependence on fossil fuels.
  • Energy-Efficient Infrastructure – Upgrading hardware and optimizing cooling techniques to maximize efficiency and reduce power consumption.
  • Sustainable Business Practices – Implementing eco-friendly policies across business operations, from waste reduction to paperless workflows.

“Web hosting providers play a crucial role in shaping a more sustainable internet,” said Scott Claeys, Founder and CEO at Rad Web Hosting. “By integrating CO₂ removal and sustainability measures into our operations, we aim to set a new standard for environmentally responsible hosting.”

By contributing a percentage of all revenues directly to CO₂ removal efforts, Rad Web Hosting also makes it easy for clients to participate by using climate-conscious hosting services.

Rad Web Hosting remains committed to continuous improvement in sustainability efforts and encourages industry-wide collaboration to address environmental challenges.

For more information about Rad Web Hosting’s sustainability initiatives, visit https://radwebhosting.com.

About Rad Web Hosting

Founded in 2015, Rad Web Hosting provides websites, hosting, cloud and VPS servers to clients across the globe. Their policy of providing customized services has paved the way them to engage with a wide scope of clients. They currently serve businesses across industries such as manufacturing, medicine, retail and ecommerce, as well as several Internet and software companies.

For more information, please visit Rad Web Hosting at: https://radwebhosting.com

Media Contact
Company Name: RadWeb, LLC
Contact Person: Scott Claeys
Email: Send Email
Phone: +1.8668444908
Address:8 The Green Ste A
City: Dover
State: Delaware
Country: United States
Website: https://www.radweb.llc

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rad Web Hosting Focuses Efforts on CO₂ Removal, Enhanced Sustainability Initiatives

Elite Maids NY Expands Post-Renovation Cleaning Services to Long Island City and Brooklyn & Launches a New, User-Friendly Website

“Elite Maids NY team: cleaning process”
Elite Maids NY is extending the area of post-renovation cleaning services to Long Island City and Brooklyn, NYC. In addition, with an aim to make the booking process easier and further improve the customer experience, the company redesigned its website and made it even more user-friendly and informative.

As more and more homeowners and businesses require reliable cleaning services after renovations, Elite Maids NY seized the opportunity for service expansion. Long Island City is a rapidly developing neighborhood in NYC filled with young professionals and families; thus, this specialized service could not be more perfectly situated. The company will bring in its expertise in post-renovation cleaning to make homes and businesses spotless and ready to move into.

“With the rapid development of Long Island City and increasing demand for reliable post-renovation cleaning, we saw a great opportunity to bring our expertise to more homeowners and businesses,” said Angela Damme, Co-founder of Elite Maids NY. “Our goal is to make the transition into newly renovated spaces seamless by providing detailed and professional cleaning services.”

Comprehensive Post-Renovation Cleaning Services

Post-renovation cleaning isn’t just dusting; it involves deep cleaning from construction debris, fine dust, and the residuals that are left behind after the renovation process. Elite Maids NY thoroughly handles every little detail in the process of giving new life to renovated places. Their services have also received excellent feedback from customers satisfied with their work quality.

New Website for Seamless Customer Experience

Apart from the expansion of services, Elite Maids NY remodeled its website for easy access by customers inquiring about the services, prices, and booking appointments with just a few clicks. The new design is neat, modern, and maintainable by an easy-to-navigate system that will ensure users will sail through without any tussles.

Apart from this, Elite Maids NY focuses a lot on eco-friendly cleaning. The company makes use of environmentally safe cleaning products, which definitely guarantees a much healthier home for its clients while reducing environmental impacts.

Because of its excellent reputation with regard to high-quality service, customer satisfaction is at a high end as Elite Maids NY continues growing and opens expert services in post-renovation cleaning for even more residents in New York City.

About Elite Maids NY

Elite Maids NY provides premier residential and commercial cleaning services in Manhattan, Brooklyn, and Long Island. This company is reliable and attentive to detail, proud of its services in house and apartment cleaning, deep cleaning, and post-renovation. Very recently, the company introduced its deep steam cleaning services, offering effective solutions to restore freshness in these spaces. Elite Maids NY continues to be one of the best options for professional cleaning services among New Yorkers due to its quality, convenience, and eco-friendly cleaning.

Media Contact
Company Name: Elite Maids NY
Contact Person: Angela Damme
Email: Send Email
Phone: 212-970-0522
Address:140 Broadway 46th floor
City: New York
State: NY
Country: United States
Website: https://elitemaidsny.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Elite Maids NY Expands Post-Renovation Cleaning Services to Long Island City and Brooklyn & Launches a New, User-Friendly Website

Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma

The Key Multiple System Atrophy Companies in the marlet include – Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.

 

DelveInsight’s “Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Multiple System Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple System Atrophy Market Forecast

 

Some of the key facts of the Multiple System Atrophy Market Report:

  • The Multiple System Atrophy market size was valued approximately USD 43 Million in 2023 and is anticipated to grow with a significant CAGR of 44.7% during the study period (2020-2034)

  • In February 2025, ATH434 by Alterity Therapeutics exhibited encouraging Phase 2 results in a randomized, double-blind trial for early-stage multiple system atrophy (MSA). The treatment, especially at a 50 mg dose, was well-tolerated and showed both clinical improvements and biomarker-based benefits.

  • In July 2024, Alterity Therapeutics announced promising interim results from the Phase II trial of ATH434 for Multiple System Atrophy. The analysis incorporated clinical and biomarker data from seven participants who were treated for six months, as well as neuroimaging data from three individuals who received treatment for 12 months. Remarkably, 43% of participants showed improved scores on the UMSARS Activities of Daily Living Scale after six months, indicating a decrease in disability.

  • In 2023, the U.S. MSA market was valued at approximately USD 38 million, representing 88% of the total market. This value is projected to rise substantially with the launch of new therapies.

  • In 2023, the combined market size of the EU4 and the UK was estimated at around USD 2.3 million, accounting for nearly 5% of the total market revenue across the 7MM.

  • In 2023, Germany held the largest market share among the EU4 and the UK, with an estimated value of approximately USD 0.57 million, followed by the UK at around USD 0.50 million. Spain had the smallest market share, reaching nearly USD 0.32 million.

  • In 2023, Japan’s MSA market was valued at approximately USD 2.98 million, with expectations of growth throughout the forecast period (2024–2034).

  • Estimates suggest that among the emerging therapies, Amlenetug (Lu AF82422) is projected to hold the largest market share, generating approximately USD 795 million in revenue across the 7MM by 2034.

  • DelveInsight’s estimates indicate that in 2023, there were approximately 70,800 prevalent cases of MSA across the 7MM. The U.S. accounted for 60% of these cases, while the EU4 and the UK contributed nearly 16%, and Japan represented 24%.

  • In 2023, the U.S. had the highest prevalence of MSA, with around 42,500 cases. This number is projected to grow at a CAGR of 1.0% through 2034.

  • In 2023, Germany had the highest prevalence of MSA among the EU4 and the UK, with approximately 2,700 cases, followed by the UK with around 2,400 cases. Spain reported the lowest prevalence, with nearly 1,500 cases.

  • In 2023, Japan recorded approximately 5,100 prevalent cases of MSA in males and 12,000 in females, with these numbers expected to increase by 2034.

  • In the U.S. in 2023, MSA cases were distributed as follows: approximately 400 in stage 0, 800 in stage 1, 2,100 in stage 2, 15,000 in stage 3, 13,000 in stage 4, and 10,000 in stage 5. These numbers are expected to increase by 2034

  • Key Multiple System Atrophy Companies: Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others

  • Key Multiple System Atrophy Therapies: Emrusolmin (TEV-56286, Anle-138b), Amlenetug (Lu AF82422), ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others

  • The Multiple System Atrophy epidemiology based on gender analyzed that males are most commonly affected as compare females in case of Multiple System Atrophy (MSA) in the 7MM

  • The Multiple System Atrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple System Atrophy pipeline products will significantly revolutionize the Multiple System Atrophy market dynamics.

 

Multiple System Atrophy Overview

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the body’s autonomic functions, such as blood pressure, heart rate, bladder function, and digestion, as well as motor control. MSA is characterized by a combination of symptoms similar to those of Parkinson’s disease, cerebellar ataxia, and autonomic failure.

 

Get a Free sample for the Multiple System Atrophy Market Report:

https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market

 

Multiple System Atrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple System Atrophy Epidemiology Segmentation:

The Multiple System Atrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Multiple System Atrophy

  • Prevalent Cases of Multiple System Atrophy by severity

  • Gender-specific Prevalence of Multiple System Atrophy

  • Diagnosed Cases of Episodic and Chronic Multiple System Atrophy

 

Download the report to understand which factors are driving Multiple System Atrophy epidemiology trends @ Multiple System Atrophy Epidemiology Forecast

 

Multiple System Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to get launched during the study period. The analysis covers Multiple System Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple System Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple System Atrophy Therapies and Key Companies

  • Emrusolmin (TEV-56286, Anle-138b): Teva Pharmaceutical/MODAG GmBH

  • Amlenetug (Lu AF82422): H. Lundbeck A/S/Genmab

  • ATH434-201/-202: Alterity Therapeutics

  • Lu AF82422: H Lundbeck A/S

  • Ampreloxetine (TD-9855): Theravance Biopharma

  • AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc

  • ION464: Ionis Pharmaceuticals, Inc.

  • ATH434: Alterity Therapeutics

  • Verdiperstat: Biohaven Pharmaceuticals, Inc.

  • TAK-341: Takeda

  • KM-819: Kainos Medicine Inc.

  • rasagiline mesylate: Teva Branded Pharma

  • Safinamide Methanesulfonate: Zambon SpA

  • AZD3241: AstraZeneca

  • NBMI: EmeraMed

  • hOMSC300: Cytora Ltd.

  • DaTSCAN™ Ioflupane: GE Healthcare

  • Droxidopa: Chelsea Therapeutics

 

Discover more about therapies set to grab major Multiple System Atrophy market share @ Multiple System Atrophy Treatment Market

 

Multiple System Atrophy Market Drivers

  • Prospect for a robust pipeline

  • New Pre-clinical MoAs

  • Increase in Multiple System Atrophy research

  • Regulatory designations

 

Multiple System Atrophy Market Barriers

  • Launch of generics

  • Diagnostic barrier

  • Limited clinical research

 

Scope of the Multiple System Atrophy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Multiple System Atrophy Companies: Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others

  • Key Multiple System Atrophy Therapies: Emrusolmin (TEV-56286, Anle-138b), Amlenetug (Lu AF82422), ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others

  • Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies

  • Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Multiple System Atrophy Unmet Needs, KOL’s views, Analyst’s views, Multiple System Atrophy Market Access and Reimbursement

 

To know more about Multiple System Atrophy companies working in the treatment market, visit @ Multiple System Atrophy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Multiple System Atrophy Market Report Introduction

2. Executive Summary for Multiple System Atrophy

3. SWOT analysis of Multiple System Atrophy

4. Multiple System Atrophy Patient Share (%) Overview at a Glance

5. Multiple System Atrophy Market Overview at a Glance

6. Multiple System Atrophy Disease Background and Overview

7. Multiple System Atrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple System Atrophy

9. Multiple System Atrophy Current Treatment and Medical Practices

10. Multiple System Atrophy Unmet Needs

11. Multiple System Atrophy Emerging Therapies

12. Multiple System Atrophy Market Outlook

13. Country-Wise Multiple System Atrophy Market Analysis (2020–2034)

14. Multiple System Atrophy Market Access and Reimbursement of Therapies

15. Multiple System Atrophy Market Drivers

16. Multiple System Atrophy Market Barriers

17. Multiple System Atrophy Appendix

18. Multiple System Atrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma

New Middle-Grade Novel Inspires Kids to Swap Screens for Outdoor Adventure

New Middle-Grade Novel Inspires Kids to Swap Screens for Outdoor Adventure

Lyon, France – March 20, 2025 – Living at the Edge of the World – Spring, the second book in a four-part seasonal series, launches today, bringing young readers another vivid tale of adventure, tradition, and belonging to a remote Shetland island in Scotland.

In an era of digital distractions, children often spend much of their time indoors, absorbed by screens. Reflecting on this shift, the author recalls a childhood filled with outdoor play—riding bikes, walking dogs, building camps, and exploring the world beyond her sofa. Inspired by these experiences, the Living at the Edge of the World series aims to rekindle a sense of adventure in kids, set in a place where nature, culture, and community take center stage.

On the remote island of Papala, home to just 30 people, WiFi is scarce, and social media’s influence is minimal—yet its presence in the story is undeniable. Rather than avoiding the topic, the author integrates it into the narrative, exploring both the power and pitfalls of digital life while advocating for a balanced approach.

“Through these stories, I hope to inspire children to step away from screens, embrace outdoor adventure, and explore different cultures and ways of life,” says S. J. Barratt.

This latest installment is a call to rediscover the thrill of adventure, the comfort of community, and the wonders of the natural world.

Book Synopsis:

Twelve-year-old twins, Tabitha and Timothy, are nearing the end of their three-month stay in Papala, Shetland before returning to London. Determined to make every moment count, they fully immerse themselves in island life—peat cutting, sheep shearing, and exploring Shetland’s rugged terrain. But when they unearth Viking artefacts buried in a peat bog, their adventure takes an unexpected turn.

Their discovery draws the attention of treasure hunters, forcing them to act fast. Using creative tactics—posting warnings, documenting their experience online, and even staging a fake bee swarm—the twins work to protect the artefacts and their new home. A final confrontation tests their courage and quick thinking, reinforcing the lessons Papala has taught them: the strength of community, the importance of preserving history, and the power of standing up for what’s right.

As they watch the artefacts find a permanent home in a museum and take in Shetland’s untamed beauty one last time, they realize that, like the island’s legends, their own story will endure. Even at twelve, they have proven that they, too, can make a difference.

Praise for Living at the Edge of the World – Spring:

“…Middle-grade readers will surely enjoy this captivating blend of murmuring tales of forgotten legends and enigmatic riddles waiting to be unraveled.” – Reedsy Discovery review by Christine L.

“…With its mix of adventure and heartfelt moments, this book makes you want to step outside, breathe in the fresh air, and look for the next adventure.” – Literary Titan

For interviews, review copies, or media inquiries, please contact:

S. J. Barratt at info@sjbstories.com, www.sjbstories.com

About the Author:

Suzanne is an award-winning children’s author and nature enthusiast whose stories are inspired by the wild landscapes of Shetland, Scotland, and the French Alps. Based in Lyon, France, she combines her love of the outdoors with her professional background in agriculture to craft stories that encourage young readers to explore and connect with nature.

Her first book in the Living at the Edge of the World series won a silver medal in the BookFest Awards for Children’s Books – Diversity & Multicultural and a Bronze Medal in the 2024 Global Book Awards for Geography & Culture.

Through her writing, she aims to spark children’s imaginations, deepen their appreciation for the natural world, and inspire a healthy balance between digital life and real-world adventure.

Living at the Edge of the World – Spring is a recipient of the 2025 Literary Titan Gold Book Award and is available for purchase at any bookstore via the IngramSpark distribution network and also Amazon.

Media Contact
Company Name: Literary Titan
Contact Person: SUZANNE BARRATT
Email: Send Email
Country: France
Website: https://www.sjbstories.com/

Traumatic Brain Injury Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approval, Medication, Epidemiology, Therapies and Companies by DelveInsight

“Traumatic Brain Injury Drug Market”
Traumatic Brain Injury companies include Supernus Pharmaceuticals, Inc., Hope Biosciences, The SanBio Group, Merz Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, CereMark Pharma, LLC, Hamad Medical Corporation, VeriNOS Pharmaceuticals GmbH, and others.

(Albany, USA) DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Traumatic Brain Injury, offering comprehensive insights into the Traumatic Brain Injury revenue trends, prevalence, and treatment landscape. The report delves into key Traumatic Brain Injury statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Traumatic Brain Injury therapies. Additionally, we cover the landscape of Traumatic Brain Injury clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Traumatic Brain Injury treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Traumatic Brain Injury space.

 

To Know in detail about the Traumatic Brain Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Traumatic Brain Injury Market Forecast

 

Some of the key facts of the Traumatic Brain Injury Market Report:

  • The Traumatic Brain Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • The total market size for TBI in the US was approximately USD 5 billion in 2023. DelveInsight’s analysis forecasts market growth driven by the introduction of new therapies. As a result, the market size is expected to expand during the study period from 2020 to 2034.
  • DelveInsight’s analysts estimate that the total market size for TBI in the EU4 and the UK was approximately USD 900 million in 2023, with expectations for further growth during the forecast period from 2024 to 2034.
  • The market size for TBI in Japan was around USD 380 million in 2023, representing 6% of the total market across the 7MM, and is projected to increase by 2034.
  • Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
  • Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
  • The Traumatic Brain Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Traumatic Brain Injury pipeline products will significantly revolutionize the Traumatic Brain Injury market dynamics.
  • According to DelveInsight’s analysis, the total number of incident cases of Traumatic Brain Injury (TBI) in the 7MM was approximately 4,254 thousand in 2023 and is expected to increase at a significant compound annual growth rate (CAGR) throughout the forecast period from 2024 to 2034.
  • Among the EU4 and UK countries, Germany reported the highest number of incident cases of Traumatic Brain Injury (TBI) in 2023, with 238 thousand cases, while Spain had the lowest at 134 thousand cases. The number of cases is anticipated to increase in the EU4 and the UK.
  • The estimates indicate that the incident population of Traumatic Brain Injury (TBI) in Japan is projected to be 325 thousand cases in 2023, but this number is expected to decline by 2034.
  • In 2023, 66% of males and 34% of females in the 7MM experienced Traumatic Brain Injury (TBI). These cases are expected to increase during the forecast period from 2024 to 2034.
  • In February 2025, Merz Pharmaceuticals GmbH announced results of a Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment
  • In January 2025, Hope Biosciences announced results of a study to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury and/or hypoxic-ischemic encephalopathy in adults.
  • In October 2023, Abalonex, LLC announced results of a Parallel Group Treatment, Phase 2A, Double-blind, 3-arm Study to Investigate Safety and Efficacy of ABX-101 Compared With Placebo in Male and Female Participants, Aged 18 to 50 Years, With Moderate-to-severe Traumatic Brain Injury

 

Traumatic Brain Injury Overview

Traumatic Brain Injury is a serious medical condition caused by a sudden impact, blow, or jolt to the head, leading to brain dysfunction. Traumatic Brain Injury can range from mild concussions to severe brain damage, affecting cognitive, physical, and emotional functions. The primary causes of Traumatic Brain Injury include falls, motor vehicle accidents, sports injuries, and violent assaults.

Traumatic Brain Injury symptoms vary based on severity and may include headaches, dizziness, memory loss, confusion, mood changes, and loss of consciousness. In severe cases, Traumatic Brain Injury can result in long-term disability, coma, or even death. Diagnosis of Traumatic Brain Injury involves neurological examinations, imaging tests such as CT scans and MRI, and cognitive assessments.

Treatment for Traumatic Brain Injury depends on the severity and includes rest, medications, rehabilitation therapies, and in critical cases, surgical interventions. Ongoing research in Traumatic Brain Injury focuses on neuroprotective drugs, stem cell therapy, and advanced rehabilitation techniques to enhance recovery.

The increasing prevalence of Traumatic Brain Injury has driven advancements in prevention strategies, including protective gear, public safety awareness, and early intervention. As medical research progresses, new therapeutic approaches for Traumatic Brain Injury continue to emerge, improving patient outcomes and quality of life.

 

Get a Free sample for the Traumatic Brain Injury Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/traumatic-brain-injury-market

 

Traumatic Brain Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Traumatic Brain Injury Epidemiology Segmentation:

The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Traumatic Brain Injury
  • Prevalent Cases of Traumatic Brain Injury by severity
  • Gender-specific Prevalence of Traumatic Brain Injury
  • Diagnosed Cases of Episodic and Chronic Traumatic Brain Injury

 

Download the report to understand which factors are driving Traumatic Brain Injury epidemiology trends @ Traumatic Brain Injury Epidemiology Forecast

 

Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Traumatic Brain Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Traumatic Brain Injury Therapies and Key Companies

  • Ronopterin (VAS203): VeriNOS Pharmaceuticals GmbH
  • CEVA101: Cellvation, Inc.
  • ABX-101: Abalonex, LLC
  • SB623 (vandefitemcel): The SanBio Group
  • Autologous HB-adMSCs: Hope Biosciences
  • [F-18]Flornaptitril: CereMark Pharma, LLC
  • ABX-101: Abalonex, LLC
  • Propranolol: Hamad Medical Corporation
  • MYOBLOC: Supernus Pharmaceuticals, Inc.
  • NT 201: Merz Pharmaceuticals GmbH

 

Discover more about therapies set to grab major Traumatic Brain Injury market share @ Traumatic Brain Injury Treatment Landscape

 

Traumatic Brain Injury Market Strengths

  • Traumatic Brain Injury is a significant global health issue, with a growing number of cases due to a rising number of head injuries and increasing awareness.
  • Advances in medical technology have led to better diagnosis, treatment, and management options for Traumatic Brain Injury, including neuroimaging techniques and neuroprotective drugs.

 

Traumatic Brain Injury Market Opportunities

  • The therapeutic market of Traumatic Brain Injury is very scarce, creating an opportunity for key market players to enter the Traumatic Brain Injury market.
  • The trend toward precision medicine opens avenues for developing targeted treatments, allowing for more effective and personalized interventions in Traumatic Brain Injury management.

 

Scope of the Traumatic Brain Injury Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
  • Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
  • Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
  • Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Traumatic Brain Injury Unmet Needs, KOL’s views, Analyst’s views, Traumatic Brain Injury Market Access and Reimbursement

 

To know more about Traumatic Brain Injury companies working in the treatment market, visit @ Traumatic Brain Injury Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Traumatic Brain Injury Market Report Introduction

2. Executive Summary for Traumatic Brain Injury

3. SWOT analysis of Traumatic Brain Injury

4. Traumatic Brain Injury Patient Share (%) Overview at a Glance

5. Traumatic Brain Injury Market Overview at a Glance

6. Traumatic Brain Injury Disease Background and Overview

7. Traumatic Brain Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Traumatic Brain Injury

9. Traumatic Brain Injury Current Treatment and Medical Practices

10. Traumatic Brain Injury Unmet Needs

11. Traumatic Brain Injury Emerging Therapies

12. Traumatic Brain Injury Market Outlook

13. Country-Wise Traumatic Brain Injury Market Analysis (2020–2034)

14. Traumatic Brain Injury Market Access and Reimbursement of Therapies

15. Traumatic Brain Injury Market Drivers

16. Traumatic Brain Injury Market Barriers

17. Traumatic Brain Injury Appendix

18. Traumatic Brain Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traumatic Brain Injury Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approval, Medication, Epidemiology, Therapies and Companies by DelveInsight